ARAF is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [3].

CBL is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains CBL status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 1, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (0 open) [3].

HRAS is an inclusion eligibility criterion in 2 clinical trials for neurofibromatosis type 1, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and neurofibromatosis type 1 as inclusion criteria, 2 are phase 2 (2 open) [3].

KIAA1549 is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains KIAA1549 status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 3 clinical trials for neurofibromatosis type 1, of which 2 are open and 1 is closed. Of the trials that contain KRAS status and neurofibromatosis type 1 as inclusion criteria, 3 are phase 2 (2 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [3].

NF1 is an inclusion eligibility criterion in 7 clinical trials for neurofibromatosis type 1, of which 6 are open and 1 is closed. Of the trials that contain NF1 status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 6 are phase 2 (5 open) [3].

NRAS is an inclusion eligibility criterion in 3 clinical trials for neurofibromatosis type 1, of which 2 are open and 1 is closed. Of the trials that contain NRAS status and neurofibromatosis type 1 as inclusion criteria, 3 are phase 2 (2 open) [3].

PTPN11 is an inclusion eligibility criterion in 2 clinical trials for neurofibromatosis type 1, of which 1 is open and 1 is closed. Of the trials that contain PTPN11 status and neurofibromatosis type 1 as inclusion criteria, 2 are phase 2 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [3].

SRC is an inclusion eligibility criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains SRC status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [3].